Developing High-Throughput Assays for M. tuberculosis Tat Pathway Inhibitors

开发结核分枝杆菌 Tat 通路抑制剂的高通量检测方法

基本信息

项目摘要

DESCRIPTION (provided by applicant): Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, is a major health problem responsible for 1.7 million deaths each year. The emergence of multiply and extensively drug resistant strains of Mtb makes the situation even more alarming as it raises concern about untreatable tuberculosis. There is an urgent need to develop new drugs to treat tuberculosis. Many bacterial pathogens possess a twin arginine translocation (Tat) pathway that exports proteins to the bacterial cell envelope or host environment. Mammalian cells do not have a Tat pathway, making this pathway an attractive candidate for novel antimicrobials. The Tat pathway of Mtb is a particularly compelling drug target: it is an essential pathway in Mtb, it exports Mtb virulence factors, and it exports the Mtb ?-lactamase that imparts resistance to ?-lactam antibiotics. In this project we will develop robust high-throughput screening (HTS) assays for identifying inhibitors of the Mtb Tat pathway. Whole-cell phenotypic assays will be developed using the fast-growing and nonpathogenic model mycobacteria M. smegmatis (Msmeg). The Tat pathway of Msmeg is not essential but it is necessary for ?-lactam resistance. In Aim 1, we will develop a primary screening assay for Tat inhibitors that is based on the ?-lactam sensitivity of Msmeg mutants lacking the Tat pathway. In Aim 2, we will develop secondary assays to distinguish compounds that elicit ?-lactam sensitivity through Tat inhibition as opposed to other mechanisms. Assays for establishing target-specificity and for testing on virulent Mtb will also be developed. In Aim 3, w will perform pilot screening to assess the effectiveness of our assays and the screening cascade with hits progressing to testing on Mtb. The compounds identified through this research will help to validate the Mtb Tat pathway as a novel drug target and they will also be valuable as the first chemical probes for studying the Tat pathway of bacteria. Upon completion of this work, we intend to apply for Fast Track entry of our screening campaign into the NIH Molecular Libraries Probe Production Centers Network.
描述(由申请人提供):结核分枝杆菌(Mtb),结核病的病原体,是一个主要的健康问题,每年造成170万人死亡。多重和广泛耐药的结核病菌株的出现使情况变得更加令人震惊,因为它引起了人们对无法治疗的结核病的担忧。迫切需要开发治疗结核病的新药。许多细菌病原体具有双精氨酸易位(达特)途径,其将蛋白质输出到细菌细胞包膜或宿主环境。哺乳动物细胞不具有达特途径,使得该途径成为新型抗微生物剂的有吸引力的候选者。结核分枝杆菌的达特途径是一个特别引人注目的药物靶点:它是结核分枝杆菌的一个重要途径,它输出结核分枝杆菌毒力因子,并且它输出结核分枝杆菌毒素。 ?-内酰胺酶,赋予耐药?-内酰胺类抗生素在这个项目中,我们将开发强大的高通量筛选(HTS)检测用于识别Mtb达特途径的抑制剂。全细胞表型分析将使用快速生长和非致病性模型分枝杆菌M。斯美格(Msmeg)。Msmeg的达特途径不是必需的,但它是必需的?内酰胺抗性。在目标1中,我们将开发一种达特抑制剂的初步筛选方法,该方法基于?缺乏达特途径的Msmeg突变体的内酰胺敏感性。在目标2中,我们将开发二次测定来区分引起?通过达特抑制内酰胺敏感性,而不是其他机制。还将开发用于建立目标特异性和检测毒性结核分枝杆菌的测定法。在目标3中,我们将进行试点筛选,以评估我们的检测方法和筛选级联的有效性,并进行结核分枝杆菌检测。通过本研究鉴定的化合物将有助于验证Mtb达特途径作为一种新的药物靶点,它们也将作为研究细菌达特途径的第一个化学探针。完成这项工作后,我们打算申请快速通道进入我们的筛选活动到NIH分子图书馆探针生产中心网络。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Miriam S. Braunstein其他文献

Miriam S. Braunstein的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Miriam S. Braunstein', 18)}}的其他基金

Effect of Microenvironment on the Activity of Mycobacteriophages for Treating Mycobacterium abscessus
微环境对治疗脓肿分枝杆菌噬菌体活性的影响
  • 批准号:
    10454361
  • 财政年份:
    2021
  • 资助金额:
    $ 37万
  • 项目类别:
Effect of Microenvironment on the Activity of Mycobacteriophages for Treating Mycobacterium abscessus
微环境对治疗脓肿分枝杆菌噬菌体活性的影响
  • 批准号:
    10287665
  • 财政年份:
    2021
  • 资助金额:
    $ 37万
  • 项目类别:
A novel protein export chaperone of Mycobacterium tuberculosis
结核分枝杆菌的新型蛋白质输出伴侣
  • 批准号:
    9892319
  • 财政年份:
    2020
  • 资助金额:
    $ 37万
  • 项目类别:
A novel protein export chaperone of Mycobacterium tuberculosis
结核分枝杆菌的新型蛋白质输出伴侣
  • 批准号:
    10079468
  • 财政年份:
    2020
  • 资助金额:
    $ 37万
  • 项目类别:
A novel protein export chaperone of Mycobacterium tuberculosis
结核分枝杆菌的新型蛋白质输出伴侣
  • 批准号:
    10541104
  • 财政年份:
    2020
  • 资助金额:
    $ 37万
  • 项目类别:
A novel protein export chaperone of Mycobacterium tuberculosis
结核分枝杆菌的新型蛋白质输出伴侣
  • 批准号:
    10312020
  • 财政年份:
    2020
  • 资助金额:
    $ 37万
  • 项目类别:
Inhaled pyrazinoic acid for tuberculosis therapy
吸入吡嗪酸治疗结核病
  • 批准号:
    9309593
  • 财政年份:
    2017
  • 资助金额:
    $ 37万
  • 项目类别:
Aerosol spectinamide-1599 therapy against tuberculosis
壮观酰胺-1599气雾剂治疗结核病
  • 批准号:
    9196248
  • 财政年份:
    2016
  • 资助金额:
    $ 37万
  • 项目类别:
Targeting SecA1 of Mycobacterium tuberculosis for Novel Drug Development
靶向结核分枝杆菌 SecA1 的新药开发
  • 批准号:
    8703436
  • 财政年份:
    2014
  • 资助金额:
    $ 37万
  • 项目类别:
Developing High-Throughput Assays for M. tuberculosis Tat Pathway Inhibitors
开发结核分枝杆菌 Tat 通路抑制剂的高通量检测方法
  • 批准号:
    8434858
  • 财政年份:
    2012
  • 资助金额:
    $ 37万
  • 项目类别:

相似海外基金

Ecological and Evolutionary Drivers of Antibiotic Resistance in Patients
患者抗生素耐药性的生态和进化驱动因素
  • 批准号:
    EP/Y031067/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Research Grant
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
  • 批准号:
    2307222
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Standard Grant
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
  • 批准号:
    2307223
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Standard Grant
Molecular Epidemiology of Antibiotic Resistance in Clostridioides difficile
艰难梭菌抗生素耐药性的分子流行病学
  • 批准号:
    502587
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
  • 批准号:
    MR/Y013131/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Research Grant
Determining structural dynamics of membrane proteins in their native environment: focus on bacterial antibiotic resistance
确定膜蛋白在其天然环境中的结构动力学:关注细菌抗生素耐药性
  • 批准号:
    MR/X009580/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Fellowship
CAREER: Systems Microbiology and InterdiscipLinary Education for Halting Environmental Antibiotic Resistance Transmission (SMILE HEART)
职业:阻止环境抗生素耐药性传播的系统微生物学和跨学科教育(SMILE HEART)
  • 批准号:
    2340818
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Continuing Grant
Reinforcing the battle at the bacterial cell wall: Structure-guided characterization and inhibition of beta-lactam antibiotic resistance signalling mechanisms
加强细菌细胞壁的战斗:β-内酰胺抗生素耐药信号机制的结构引导表征和抑制
  • 批准号:
    480022
  • 财政年份:
    2023
  • 资助金额:
    $ 37万
  • 项目类别:
    Operating Grants
The spread of antibiotic resistance in bacteria-plasmid networks
抗生素耐药性在细菌-质粒网络中的传播
  • 批准号:
    BB/X010473/1
  • 财政年份:
    2023
  • 资助金额:
    $ 37万
  • 项目类别:
    Fellowship
An RNA Nanosensor for the Diagnosis of Antibiotic Resistance in M. Tuberculosis
用于诊断结核分枝杆菌抗生素耐药性的 RNA 纳米传感器
  • 批准号:
    10670613
  • 财政年份:
    2023
  • 资助金额:
    $ 37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了